Minister Chrystia Freeland announced new program to provide up to $50 million over five years in direct financial support to small and medium-sized enterprises (SMEs) seeking to develop export opportunities.
The "Company of the Year" award was presented to Fedora Pharmaceuticals at BioAlberta's annual Awards Gala in Edmonton on November 24, 2015.
BioAlberta hosted its 16th Annual AGM and Awards Gala in Edmonton, with an audience of over 150 representatives from industry, government and educational institutions. The event recognized companies and individuals ...
SolAeroMed Inc., announce its completion of patient recruitment for core components of its Phase IIa Proof of Concept data for its S-1226™ technology.
Quest PharmaTech’s subsidiary, OncoQuest, Closes US $13M Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
Unique PGX enabling technology expected to generate novel bio-based products with improved purity and functionality in several industrial applications.
Jeremy Webster, Deloitte LLP, and Mel Wong, BioAlberta, will present the findings of the 2015 Alberta State of the Industry Report in Edmonton on November 3rd and in Calgary on November 5th.
Young scientists and entrepreneurs are taking their new water quality detection technology "FRED" to the next stage in California.
BioNeutra has acquired a manufacturing facility in Edmonton that it will use to start a production line for its specialized food ingredients.
An exclusive license agreement between SinoVeda Canada Inc. and Exzell Pharma to commercialize SinoVeda’s patented multi-element calcium supplement.
Aquila Diagnostics Inc. announces its participation in a project with the PATH Malaria Vaccine Initiative to improve testing for malaria infectiousness.
Genome Canada is the primary funding and information resource relating to genomics and proteomics research in Canada. A few current funding opportunities are: LSARP, GAPP and DIG.
Quest PharmaTech, an Edmonton-based pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has closed a $1,000,000 unit offering private placement.
GIC, an Edmonton based pharmaceutical manufacturer, perfects ultra-pure nucleoside production for anti-viral and anti-cancer use.
New ingredient for cosmetic facial scrubs to address concerns of freshwater pollution from synthetic, non-degradable plastic microbeads.